We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Regeneron Pharma (REGN) Disappoint in Q3 Earnings?
Read MoreHide Full Article
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is scheduled to release third-quarter 2017 results on Nov 8, before the opening bell.
Last quarter, Regeneron Pharma beat earnings expectations by 30.3%. The company’s performance has been mixed so far. In the last four quarters, it surpassed earnings estimates on two occasions and missed in two. Overall, the company has recorded an average positive earnings surprise of 10.1%. Let’s see how things are shaping up for this quarter.
Regeneron’s stock has lost 2.3% year to date compared to the industry’s decline of 1.2%.
Factors Influencing This Quarter
Regeneron Pharma’s key growth driver, Eylea, is likely to continue to contribute to the company’s top-line growth. Based on a strong first half, the company raised its sales guidance for Eylea. In 2017, Regeneron Pharma expects Eylea net sales to grow around 10% (earlier guidance: growth in single digits) in the United States. The Zacks Consensus Estimate for the drug’s sales (worldwide basis) is currently $1.4 billion for the quarter.
We note that Regeneron Pharma has a global development and commercialization agreement with Bayer AG (BAYRY - Free Report) outside the United States for Eylea. Product revenues from ex-U.S. Eylea sales are recorded by Bayer.
Meanwhile, Regeneron Pharma is working on expanding Eylea label into additional indications. While a phase III study (PANORAMA) is evaluating Eylea for the treatment of moderately severe to severe non-proliferative diabetic retinopathy in patients without DME, another phase III study (in Japan) is evaluating it for neovascular glaucoma.
Apart from Eylea, investors will remain focused on the uptake of new drugs — Kevzara and Dupixent. Kevzara (sarilumab), an anti interleukin (IL)-6 receptor monoclonal antibody was approved in Canada for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response to or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs and was approved by the FDA in May 2017.
The FDA also approved Dupixent (dupilumab) Injection for the treatment of adults with moderate-to-severe atopic dermatitis (AD). The initial uptake of the drug is encouraging. The drug was approved in Europe also. The company is also evaluating the drug for treating asthma in adults (LIBERTY ASTHMA QUEST study). A phase III study of Dupixent in pediatric patients (6-11 years of age) with uncontrolled persistent asthma was initiated in second-quarter 2017.
Hence, focus will be on the company’s performance, particularly Eylea and Dupixient uptake during the third-quarter earnings call. Investors are also expected to await updates on the company’s pipeline.
Meanwhile, Regeneron Pharma and partner Sanofi (SNY - Free Report) are allowed to continue to sell their PCSK9 inhibitor, Praluent, in the United States by the Court of Appeals for the Federal Circuit following a favorable ruling. This bodes well and we expect the management to throw more light on the upside if any. However, sales of the drug have failed to impress so far.
Earnings Whispers
Our proven model does not conclusively show that Regeneron Pharma is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +1.6%. This is because both the Most Accurate estimate is $3.99 while the Zacks Consensus Estimate is $3.93. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Regeneron Pharma currently carries a Zacks Rank #4 (Sell). Note that, we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) before going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Regeneron Pharmaceuticals, Inc. Price and EPS Surprise
Here is a health care stock that you may want to consider instead, as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Will Regeneron Pharma (REGN) Disappoint in Q3 Earnings?
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is scheduled to release third-quarter 2017 results on Nov 8, before the opening bell.
Last quarter, Regeneron Pharma beat earnings expectations by 30.3%. The company’s performance has been mixed so far. In the last four quarters, it surpassed earnings estimates on two occasions and missed in two. Overall, the company has recorded an average positive earnings surprise of 10.1%. Let’s see how things are shaping up for this quarter.
Regeneron’s stock has lost 2.3% year to date compared to the industry’s decline of 1.2%.
Factors Influencing This Quarter
Regeneron Pharma’s key growth driver, Eylea, is likely to continue to contribute to the company’s top-line growth. Based on a strong first half, the company raised its sales guidance for Eylea. In 2017, Regeneron Pharma expects Eylea net sales to grow around 10% (earlier guidance: growth in single digits) in the United States. The Zacks Consensus Estimate for the drug’s sales (worldwide basis) is currently $1.4 billion for the quarter.
We note that Regeneron Pharma has a global development and commercialization agreement with Bayer AG (BAYRY - Free Report) outside the United States for Eylea. Product revenues from ex-U.S. Eylea sales are recorded by Bayer.
Meanwhile, Regeneron Pharma is working on expanding Eylea label into additional indications. While a phase III study (PANORAMA) is evaluating Eylea for the treatment of moderately severe to severe non-proliferative diabetic retinopathy in patients without DME, another phase III study (in Japan) is evaluating it for neovascular glaucoma.
Apart from Eylea, investors will remain focused on the uptake of new drugs — Kevzara and Dupixent. Kevzara (sarilumab), an anti interleukin (IL)-6 receptor monoclonal antibody was approved in Canada for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response to or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs and was approved by the FDA in May 2017.
The FDA also approved Dupixent (dupilumab) Injection for the treatment of adults with moderate-to-severe atopic dermatitis (AD). The initial uptake of the drug is encouraging. The drug was approved in Europe also. The company is also evaluating the drug for treating asthma in adults (LIBERTY ASTHMA QUEST study). A phase III study of Dupixent in pediatric patients (6-11 years of age) with uncontrolled persistent asthma was initiated in second-quarter 2017.
Hence, focus will be on the company’s performance, particularly Eylea and Dupixient uptake during the third-quarter earnings call. Investors are also expected to await updates on the company’s pipeline.
Meanwhile, Regeneron Pharma and partner Sanofi (SNY - Free Report) are allowed to continue to sell their PCSK9 inhibitor, Praluent, in the United States by the Court of Appeals for the Federal Circuit following a favorable ruling. This bodes well and we expect the management to throw more light on the upside if any. However, sales of the drug have failed to impress so far.
Earnings Whispers
Our proven model does not conclusively show that Regeneron Pharma is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +1.6%. This is because both the Most Accurate estimate is $3.99 while the Zacks Consensus Estimate is $3.93. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Regeneron Pharma currently carries a Zacks Rank #4 (Sell). Note that, we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) before going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Regeneron Pharmaceuticals, Inc. Price and EPS Surprise
Regeneron Pharmaceuticals, Inc. Price and EPS Surprise | Regeneron Pharmaceuticals, Inc. Quote
Stock That Warrants a Look
Here is a health care stock that you may want to consider instead, as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Mylan N.V. has an Earnings ESP of +3.6% and currently carries a Zacks Rank #2. The company is expected to release third-quarter results on Nov 6. You can see the complete list of today’s Zacks #1 Rank stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>